Vancouver-based psychedelic drugs company Clearmind Medicine has entered a licensing agreement with Yissum Research Development Company at the Hebrew University of Jerusalem. The collaboration is focused on the development and utilization of next-gen psychedelic compounds for treating addiction and mental health disorders.
Under the terms of the agreement, Clearmind will receive exclusive worldwide rights to develop, research, manufacture, market, and commercialize products derived from an upcoming patent of psychedelic compounds.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.